Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTN NASDAQ:LFCR NASDAQ:NKTX NASDAQ:PDSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTNHillstream Biopharma$2.97+10.8%$3.16$1.08▼$9.08$187.43M1.411.24 million shs6.15 million shsLFCRLifecore Biomedical$5.17-4.1%$5.14$3.63▼$8.98$202.18M1.06188,541 shs874,619 shsNKTXNkarta$2.83+1.8%$2.92$1.63▼$3.65$198.90M0.91533,639 shs1.37 million shsPDSBPDS Biotechnology$0.89-0.6%$1.09$0.51▼$1.55$49.90M1.57791,760 shs630,991 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTNHillstream Biopharma+10.82%-11.34%-8.05%-6.31%+296,999,900.00%LFCRLifecore Biomedical-4.08%-6.68%+7.26%+41.26%-38.01%NKTXNkarta+1.80%-1.05%-11.29%+37.38%+58.99%PDSBPDS Biotechnology-0.62%-6.96%-19.95%+64.11%-41.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTNHillstream Biopharma$2.97+10.8%$3.16$1.08▼$9.08$187.43M1.411.24 million shs6.15 million shsLFCRLifecore Biomedical$5.17-4.1%$5.14$3.63▼$8.98$202.18M1.06188,541 shs874,619 shsNKTXNkarta$2.83+1.8%$2.92$1.63▼$3.65$198.90M0.91533,639 shs1.37 million shsPDSBPDS Biotechnology$0.89-0.6%$1.09$0.51▼$1.55$49.90M1.57791,760 shs630,991 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTNHillstream Biopharma+10.82%-11.34%-8.05%-6.31%+296,999,900.00%LFCRLifecore Biomedical-4.08%-6.68%+7.26%+41.26%-38.01%NKTXNkarta+1.80%-1.05%-11.29%+37.38%+58.99%PDSBPDS Biotechnology-0.62%-6.96%-19.95%+64.11%-41.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTNHillstream Biopharma 1.00SellN/AN/ALFCRLifecore Biomedical 2.00Hold$6.5025.73% UpsideNKTXNkarta 2.83Moderate Buy$10.75279.86% UpsidePDSBPDS Biotechnology 2.33Hold$9.00912.94% UpsideCurrent Analyst Ratings BreakdownLatest PDSB, NKTX, LFCR, and CNTN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026NKTXNkarta Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026NKTXNkarta TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/17/2026CNTNHillstream Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/16/2026LFCRLifecore Biomedical Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $6.506/3/2026CNTNHillstream Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026NKTXNkarta EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$9.005/18/2026NKTXNkarta EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/15/2026CNTNHillstream Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026NKTXNkarta Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.005/7/2026LFCRLifecore Biomedical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)4/29/2026LFCRLifecore Biomedical Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.50 ➝ $6.00(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTNHillstream BiopharmaN/AN/AN/AN/A$10.92 per shareN/ALFCRLifecore Biomedical$128.87M1.50N/AN/A$0.42 per share12.31NKTXNkartaN/AN/AN/AN/A$4.40 per shareN/APDSBPDS BiotechnologyN/AN/AN/AN/A$0.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTNHillstream Biopharma-$35.92M-$1.15N/AN/AN/AN/A-31.50%-24.72%N/ALFCRLifecore BiomedicalN/A-$0.94N/AN/AN/A-25.43%-1,643.15%-14.40%8/5/2026 (Estimated)NKTXNkarta-$104.08M-$1.34N/AN/AN/AN/A-30.90%-24.20%8/11/2026 (Estimated)PDSBPDS Biotechnology-$34.50M-$0.67N/AN/AN/AN/A-346.02%-102.36%8/12/2026 (Estimated)Latest PDSB, NKTX, LFCR, and CNTN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026PDSBPDS Biotechnology-$0.15-$0.13+$0.02-$0.13N/AN/A5/12/2026Q1 2026NKTXNkarta-$0.39-$0.37+$0.02-$0.37N/AN/A5/6/2026Q1 2026LFCRLifecore Biomedical-$0.29-$0.43-$0.14-$0.43$25.96 million$23.19 million3/31/2026Q4 2025CNTNHillstream BiopharmaN/A$0.54N/A$0.54N/AN/A3/30/2026Q4 2025PDSBPDS Biotechnology-$0.20-$0.14+$0.06-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTNHillstream BiopharmaN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTNHillstream BiopharmaN/A37.7637.76LFCRLifecore BiomedicalN/A3.792.41NKTXNkartaN/A12.9612.96PDSBPDS Biotechnology2.732.262.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTNHillstream Biopharma1.16%LFCRLifecore Biomedical83.36%NKTXNkarta80.54%PDSBPDS Biotechnology26.84%Insider OwnershipCompanyInsider OwnershipCNTNHillstream Biopharma6.70%LFCRLifecore Biomedical32.68%NKTXNkarta9.80%PDSBPDS Biotechnology9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTNHillstream Biopharma269.81 million65.13 millionN/ALFCRLifecore Biomedical69037.51 million25.25 millionOptionableNKTXNkarta14071.54 million64.53 millionOptionablePDSBPDS Biotechnology2055.82 million50.68 millionOptionablePDSB, NKTX, LFCR, and CNTN HeadlinesRecent News About These CompaniesPDS Biotechnology Sets 2026 Annual Stockholders Meeting DateJune 15, 2026 | tipranks.comHere's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom FisherJune 10, 2026 | zacks.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2026 Earnings Call TranscriptMay 15, 2026 | insidermonkey.comPDS Biotechnology Q1 2026 Earnings Call: Complete TranscriptMay 15, 2026 | finance.yahoo.comPDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ...May 15, 2026 | finance.yahoo.comPDS Biotechnology Corporation Schedules Investor Webcast for Business and Clinical UpdateMay 13, 2026 | quiverquant.comQPDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate UpdateMay 13, 2026 | markets.businessinsider.comPDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate UpdateMay 13, 2026 | globenewswire.comPDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial ResultsMay 6, 2026 | globenewswire.comPDS Biotechnology Corp.April 22, 2026 | barrons.comB. Riley Securities Sticks to Their Buy Rating for PDS Biotechnology (PDSB)April 17, 2026 | theglobeandmail.comPDSB stock hits 37-week high — here’s the latest on its therapy to treat metastatic colorectal cancerApril 15, 2026 | msn.comPDS Biotechnology Announces Promising Phase 2 Trial Results of PDS01ADC for Treatment of Colorectal Liver MetastasesApril 15, 2026 | quiverquant.comQPDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) TrialApril 15, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Eli Lilly & Co (LLY) and Praxis Precision Medicines (PRAX)April 7, 2026 | theglobeandmail.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 earnings call transcriptApril 1, 2026 | msn.comPDS Biotechnology Corp (PDSB) Q4 2025 Earnings Call Highlights: Financial Discipline Amid ...March 31, 2026 | finance.yahoo.comPDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call TranscriptMarch 30, 2026 | seekingalpha.comPDS Biotechnology: Q4 Earnings SnapshotMarch 30, 2026 | finance.yahoo.comPDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical AdvancementMarch 30, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePDSB, NKTX, LFCR, and CNTN Company DescriptionsHillstream Biopharma NASDAQ:CNTN$2.97 +0.29 (+10.82%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$3.04 +0.07 (+2.32%) As of 06/26/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.Lifecore Biomedical NASDAQ:LFCR$5.17 -0.22 (-4.08%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$5.16 -0.01 (-0.19%) As of 06/26/2026 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Nkarta NASDAQ:NKTX$2.83 +0.05 (+1.80%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$2.80 -0.04 (-1.24%) As of 06/26/2026 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.PDS Biotechnology NASDAQ:PDSB$0.89 -0.01 (-0.62%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$0.90 +0.01 (+0.84%) As of 06/26/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout Palantir’s Valuation Problem Just Met 2 New Growth Catalysts Micron’s HBM Surge Could Redefine the AI Growth Story Carnival's Second Quarter: Is the Stock Still Complicated? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
